Il successivo lotto di documenti sui vaccini Pfizer da parte dell’ FDA è stato prodotto, disponibile all’indirizzo Public Health and Medical Professionals for Transparency.
Link ai nuovi documenti (pagine 1 e 2 su PHMPT):
Pagina 1
• FDA-CBER-2021-5683-0208521 to -0216666_125742_S1_M5_c4591001-S-Supp-D-suppvs.zip
• FDA-CBER-2021-5683-0205318 to -0208520_125742_S1_M5_c4591001-S-Supp-D-ex.zip
• FDA-CBER-2021-5683-0196049 to -0205317_125742_S1_M5_c4591001-S-Supp-D-ce.zip
• FDA-CBER-2021-5683-0187906 to -0196048_125742_S1_M5_c4591001-S-D-suppvs.zip
• FDA-CBER-2021-5683-0182981 to -0187905_125742_S1_M5_c4591001-S-D-suppmh.zip
• FDA-CBER-2021-5683-0180191 to -0182980_125742_S1_M5_c4591001-S-D-suppis.zip
• FDA-CBER-2021-5683-0178319 to -0180190_125742_S1_M5_c4591001-S-D-suppho.zip
• FDA-CBER-2021-5683-0174607 to -0178318_125742_S1_M5_c4591001-S-D-suppdv.zip
• FDA-CBER-2021-5683-0171524 to -0174606_125742_S1_M5_c4591001-S-D-suppds.zip
• FDA-CBER-2021-5683-0169082 to -0171523_125742_S1_M5_c4591001-S-D-suppdm.zip
• FDA-CBER-2021-5683-0168683 to -0169081_125742_S1_M5_c4591001-S-D-suppcm.zip
• FDA-CBER-2021-5683-0165893 to -0168682_125742_S1_M5_c4591001-S-D-is.zip
• FDA-CBER-2021-5683-0162690 to -0165892_125742_S1_M5_c4591001-S-D-ex.zip
• FDA-CBER-2021-5683-0159487 to -0162689_125742_S1_M5_c4591001-S-D-ec.zip
• FDA-CBER-2021-5683-0158560 to -0159486_125742_S1_M5_c4591001-S-D-dv.zip
• FDA-CBER-2021-5683-0149082 to -0158559_125742_S1_M5_c4591001-S-D-ce.zip
• FDA-CBER-2021-5683-0142307 to -0149081_125742_S1_M5_c4591001-A-Supp-D-adcevd.zip
• 125742_S1_M5_CRF_c4591001 1081 10811194 reissue.pdf
• 125742_S1_M5_CRF_c4591001 1015 10151238.pdf
• 125742_S1_M5_CRF_c4591001 1015 10151225.pdf
• 125742_S1_M5_CRF_c4591001 1015 10151134.pdf
• STN 125742 0 0 Section 2.5 Clinical Overview reissue.pdf
• 125742_S1_M5_CRF_c4591001 1128 11281009 reissue.pdf
• 125742_S1_M5_CRF_c4591001 1015 10151089.pdf
• 125742_S1_M5_CRF_c4591001 1015 10151047.pdf
Pagina 2
• 125742_S1_M5_CRF_c4591001 1015 10151071.pdf
• 125742_S1_M5_CRF_c4591001 1015 10151035.pdf
• 125742_S1_M5_CRF_c4591001 1015 10151011.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131786.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131718.pdf
• 125742_S1_M5_CRF_c4591001 1015 10151101.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131658.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131656.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131653.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131554.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131517.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131255.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131386.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131229.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131699.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131176.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131165.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131089.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131084.pdf
• 125742_S1_M5_CRF_c4591001 1012 10121112.pdf
• 125742_S1_M5_CRF_c4591001 1012 10121163.pdf
• 125742_S1_M5_CRF_c4591001 1011 10111181.pdf
• 125742_S1_M5_CRF_c4591001 1012 10121097.pdf
• 125742_S1_M5_CRF_c4591001 1013 10131190.pdf
• 125742_S1_M5_CRF_c4591001 1009 10091123.pdf
Pagina 3
• 125742_S1_M5_CRF_c4591001 1008 10081667.pdf
• 125742_S1_M5_CRF_c4591001 1008 10081628.pdf
• 125742_S1_M5_CRF_c4591001 1011 10111029.pdf
• 125742_S1_M5_CRF_c4591001 1008 10081603.pdf
• 125742_S1_M5_CRF_c4591001 1009 10091149.pdf
• 125742_S1_M5_CRF_c4591001 1009 10091135.pdf
• 125742_S1_M5_CRF_c4591001 1009 10091128.pdf
• 125742_S1_M5_CRF_c4591001 1008 10081152.pdf
• 125742_S1_M5_CRF_c4591001 1007 10071443.pdf
• 125742_S1_M5_CRF_c4591001 1008 10081056.pdf
• 125742_S1_M5_CRF_c4591001 1007 10071441.pdf
• 125742_S1_M5_CRF_c4591001 1007 10071347.pdf
• 125742_S1_M5_CRF_c4591001 1007 10071315.pdf
• 125742_S1_M5_CRF_c4591001 1007 10071306.pdf
• 125742_S1_M5_CRF_c4591001 1007 10071280.pdf
• 125742_S1_M5_CRF_c4591001 1007 10071276.pdf
• 125742_S1_M5_CRF_c4591001 1007 10071192.pdf
• 125742_S1_M5_CRF_c4591001 1007 10071159.pdf
• 125742_S1_M5_CRF_c4591001 1007 10071124.pdf
• 125742_S1_M5_CRF_c4591001 1007 10071117.pdf
• 125742_S1_M5_CRF_c4591001 1007 10071101.pdf
• 125742_S1_M5_CRF_c4591001 1007 10071097.pdf
• 125742_S1_M5_CRF_c4591001 1007 10071050.pdf
• 125742_S1_M5_CRF_c4591001 1008 10081337.pdf
• 125742_S1_M5_CRF_c4591001 1008 10081184.pdf
Pagina 4
• 125742_S1_M5_5351_c4591001 interim mth6 publications.pdf
• 125742_S1_M5_5351_c4591001 interim mth6 patient batches.pdf
• 125742_S1_M5_5351_c4591001 fa interim protocol deviations sensitive.pdf
• 125742_S1_M5_5351_c4591001 fa interim discontinued patients.pdf
• 125742_S1_M5_5351_c4591001 fa interim patient batches.pdf
• 125742_S1_M5_5351_c4591001 fa interim adverse events.pdf
• 125742_S1_M5_5314_shi sop 10011.pdf
• 125742_S1_M2_summary biopharm.pdf
• 125742_S1_M5_5351_c4591001 interim mth6 randomization.pdf
Source: Pulic Health and Medical Professionals for Transparency
Siamo entusiasti di comunicarvi la partnership tra Oggi Notizie e Anime Libere, un social libero da CENSURE, Intelligenza Artificiale, e algoritmi di controllo. Con il nuovo social Anime Libere hai la possibilità di pubblicare tu stesso notizie e argomenti di tuo interesse, aprire gruppi pubblici o privati e interagire con tutti gli iscritti attraverso una chat in tempo reale. Anime Libere preserva e promuove la possibilità di esprimersi e condividere opinioni, incoraggiando una discussione rispettosa e civile tra gli utenti.
Anime Libere non solo è totalmente gratuito, ma chi volesse sostenere il progetto sottoscrivendo un abbonamento avrà la possibilità di GUADAGNARE invitando amici ad iscriversi e monetizzare tramite i contenuti che pubblicherà
